The trademark application CYRAMZA was filed by ImClone LLC, a Limited Liability Company (the "Applicant"). The application was published for oppositions on July 29, 2014, and it was registered by office on November 5, 2014 without any oppositions.
The application was filed in English (Italian was selected as the second language).
The renewal of the trademark was recorded by the office on February 5, 2024.
Change of name and professional address of the trademark registration was recorded on December 19, 2018. Appointment and Replacement of representative of the trademark registration was recorded on April 4, 2019.
Goods And Services
The mark was filed in class 5 with following description of goods:
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment, prevention and diagnosis of alcohol use disorders, Alzheimer's, anxiety disorders, atherosclerosis, autoimmune diseases and disorders, blood disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cholesterol disorders, cystic fibrosis, dementia and dermatological diseases and disorders
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment, prevention and diagnosis of diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders and pain
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment, prevention and diagnosis of pancreatic diseases and disorders, psychiatric disorders, reproductive system diseases and disorders, sleep disorders and urological disorders
Antidepressants
Diagnostic agents, preparations and substances for medical purposes
Radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative amyloid diseases